Vertex Pharmaceuticals prioritizes renal and endocrine growth over cystic fibrosis

Vertex Pharmaceuticals management shifted its focus toward emerging renal and endocrine franchises during its fiscal Q2 2026 earnings call, signaling a strategic pivot away from its core cystic fibrosis business. The company now argues that its new pipelines could rival its legacy franchise in revenue, a departure from earlier statements that emphasized sustained growth in cystic fibrosis over the short, medium, and long term.

During the call in August, executives detailed the rationale behind an agreement to acquire Crinetics for approximately $8.8 billion, net of acquired cash. Management stated this transaction would add a fifth pillar for the company in rare endocrine diseases. This emphasis on non-cystic fibrosis products contrasts with fiscal Q3 2024 commentary, where management highlighted the durability of the cystic fibrosis franchise. While the company still describes cystic fibrosis as having sustained growth potential, the recent dialogue spends more time on what comes after the current flagship treatments.

The shift in narrative occurs while cystic fibrosis remains the dominant revenue driver. TRIKAFTA/KAFTRIO, Vertex’s primary cystic fibrosis medicine, accounted for 85.9% of company revenue in fiscal 2025. Growth for this treatment slowed to 0.7% in that period, down from 14.5% in fiscal 2024. However, global cystic fibrosis revenue still rose 11% year-over-year in fiscal Q2 2026. Management attributed this volume growth primarily to strong uptake of ALYFTREK, a newer cystic fibrosis medicine, in the United States.

Newer medicines outside of cystic fibrosis are currently small but growing rapidly. CASGEVY and JOURNAVX combined to generate $126 million of the $3.33 billion in total revenue reported for fiscal Q2 2026. CASGEVY, a one-time gene therapy for sickle cell disease and beta thalassemia, earned $76 million, up about 75% from the prior quarter. JOURNAVX, a pain medicine, brought in $50 million, up about 70% on the same basis. For full-year 2026, management expects $500 million or more from these non-cystic fibrosis products, against total revenue guidance of $13.1 billion to $13.2 billion.

Longer-term bets rely on the Crinetics acquisition. Management estimates peak sales of the two lead Crinetics medicines, PALSONIFY and atumelnant, at about $5 billion. The company expects the deal to contribute to non-GAAP operating income in 2029. In the renal space, Vertex has built a commercial team to launch povetacicept. The FDA has set November 30, 2026, as its decision date for this medicine.

Caveats remain regarding the sustainability of current growth rates. Management noted that part of the recent cystic fibrosis growth came from order timing and currency movements outside the U.S., as well as sales channels restocking after running down inventory in the first quarter. If cystic fibrosis growth fades, the newer medicines are currently too small to fill any gap in 2026. Vertex held its third-quarter calls in early November in each of the last two years. When the company reports on or around February 10, 2027, full-year revenue from non-cystic fibrosis products will be measured against the $500 million target management expects.